International Atomic Energy Agency-Sponsored Multination Study of Intra-Arterial Rhenium-188-Labeled Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results With Special Emphasis on Prognostic Value of Dosimetric Study
| Autor: | Patricia Bernal, Trinh Thi Minh Chau, Jean-Luc Raoul, Sundram Fx, Chaitanya R. Divgi, Ruben Ogbac, Janez Stare, Shaoliang Chen, Pat Zanzonico, Ajit Kumar Padhy, Maung Maung Saw, Maurizio Dondi, Pawana Pusuwan, Erdenechimeg Sereegotov, Jae Min Jeong, John R. Buscombe, Gaj Vidmar, Ajay Kumar |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Carcinoma Hepatocellular Carcinoma medicine Intra arterial Humans Radiology Nuclear Medicine and imaging Aged Aged 80 and over Radioisotopes business.industry Radiotherapy Planning Computer-Assisted Liver Neoplasms International Agencies Iodized Oil Middle Aged Nuclear Energy Prognosis medicine.disease Radioconjugate Clinical trial Rhenium Injections Intra-Arterial Multicenter study Tumor progression Hepatocellular carcinoma Lipiodol Female business Nuclear medicine medicine.drug |
| Zdroj: | Seminars in Nuclear Medicine. 38:S40-S45 |
| ISSN: | 0001-2998 |
| Popis: | A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 ((188)Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma. During 5 years, 185 patients received at least 1 treatment of radioconjugate, and 51 were retreated. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated after a "scout" dose of radioconjugate. The total injected activity, including the scout dose during the first treatment, ranged from 21 to 364 mCi (mean, 108 mCi/4 GBq). Immediate and late side-effects were minimal. Tumor size could be evaluated in 88 patients. Among these patients, the objective response rate was 25%; stable disease was observed in 53% and tumor progression in 22%. With a median follow-up of 455 days, the estimated 12- and 24-month overall survival was 46% and 23%. This multicenter study shows that (188)Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect